Therefore, for the prevention and/or treatment of brain injuries, the determination of quantitative biomarkers, such as biochemical parameters (e.g., NfL) of brain damage, to diagnose subclinical lesions at phases when conventional monitoring tools are unable to detect them, could be extremely helpful. The gene discussed is NEFL; the disease is brain injury.